Skip to main content
main-content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

03-10-2017 | Gestational diabetes | Review | Article

Gestational diabetes mellitus: An updated overview

This review provides an update on the clinical aspects of gestational diabetes, including the epidemiology, etiology, long-term consequences, diagnosis, treatment, and prevention of the condition.

SGLT2 inhibitors: The story so far

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class.

09-15-2017 | Continuous glucose monitoring | EASD 2017 | News

CGM use during pregnancy improves maternal glycemic control, neonatal outcomes

The CONCEPTT trial results suggest that the use of continuous glucose monitoring by pregnant women with type 1 diabetes improves glycemic control and neonatal outcomes relative to standard glucose monitoring.

Latest from across the site

09-25-2017 | Genetics | News

Genetic variants may impact HbA1c diagnostic threshold in African Americans

Ancestral differences in the impact genetic variants have on glycated hemoglobin can substantially affect the performance of HbA1c as a diagnostic test for type 2 diabetes, results of a large trans-ethnic genome-wide meta-analysis show.

Source:

PLoS Med 2017; 14: e1002383

09-22-2017 | Physical activity | News

News in brief

PURE study shows global physical activity benefits

The PURE study shows that the cardiovascular disease and mortality risk reductions attainable with regular physical activity apply regardless of whether people live in countries with high, middle, or low income.

09-22-2017 | Older adults | EASD 2017 | News

Optimizing outcomes: System and patient factors

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

Source:

EASD 2017; Lisbon, Portugal: 11–15 September

09-22-2017 | Insulin glargine | EASD 2017 | News

News in brief

Higher dose of insulin glargine supported for type 2 diabetes

Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

09-22-2017 | Medication adherence | EASD 2017 | News

News in brief

Sliding scale for medication adherence and CVD protection

Adherence to lipid-lowering drugs is crucial for reducing cardiovascular disease risk among patients with type 2 diabetes, but taking only some of the prescribed medication is better than none at all, study results suggest.

09-21-2017 | Type 2 diabetes | EASD 2017 | News

Novel compounds show promise for type 2 diabetes

Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.

Source:

EASD 2017; Lisbon, Portugal: 11–15 September

Meet our Editorial Board

Lori BerardSanjay KalraJay ShubrookProfessor John WildingCarol Wysham

New Content Item Meet our Advisory Board

image credits